Compare BZUN & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BZUN | MOLN |
|---|---|---|
| Founded | 2007 | 2004 |
| Country | China | Switzerland |
| Employees | 6887 | N/A |
| Industry | Catalog/Specialty Distribution | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.7M | 144.0M |
| IPO Year | N/A | 2021 |
| Metric | BZUN | MOLN |
|---|---|---|
| Price | $2.58 | $4.33 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.38 |
| AVG Volume (30 Days) | ★ 348.6K | 3.6K |
| Earning Date | 05-20-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.91 | N/A |
| Revenue Next Year | $6.66 | $374.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.07 | $3.36 |
| 52 Week High | $4.88 | $5.36 |
| Indicator | BZUN | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 58.16 | 50.44 |
| Support Level | $2.31 | $4.04 |
| Resistance Level | $2.94 | $4.51 |
| Average True Range (ATR) | 0.18 | 0.19 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 84.68 | 61.43 |
Baozun Inc is engaged to provide its customers with end-to-end e-commerce solutions including the sales of apparel, home and electronic products, online store design and setup, visual merchandising and marketing, online store operations, customer services, warehousing and order fulfillment, as well as the holistic brand management, including strategy and tactic positioning, branding and marketing, retail and e-commerce operations, supply chain and logistics, and technology empowerment. It has two operating segments: E-Commerce (encompassing BEC and BZI) and Brand Management (representing BBM). The company generates maximum of its revenue from E-Commerce (encompassing BEC and BZI) segment.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.